Evidence map›Paper›PMID 40242576›Full record

ArticleACS pharmacology & translational science2025

Chemistry Outside the Flask: Redefining Selectivity In Vivo with Image Guidance.

Erik Cressman, Danielle Stolley, Natalie Fowlkes, Shubhneet Warar, Edd Felix, Waldemar Priebe, Steve Parrish, David Fuentes

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Erik CressmanDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.ORCID https://orcid.org/0000-0002-8671-9862
Danielle StolleyFlow Cytometry & Cellular Imaging Core Facility, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Natalie FowlkesDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Shubhneet WararDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Edd FelixDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Waldemar PriebeDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Steve ParrishDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
David FuentesDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.

Funding

Characterization of endovascular ablative therapies with computational modelingR21CA260016 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUENTES, DAVID · 2022 to 2023
$413k
NCI NIH HHS R21 CA260016
6 · The paper itself

Abstract

Fundamental to drug dosing and formulation strategies are the therapeutic index and maintaining a plasma concentration within a safe but therapeutic window. This holds true for oral, intravenous, transdermal, and intramuscular delivery methods. A key factor in plasma concentration is the half-life for any drug, because this affects the appropriate dose. Drugs with a very short half-life pose a particular challenge. Therefore, highly reactive compounds are not generally used for therapeutic purposes. However, targeted delivery under direct visualization, combined with cessation of blood flow in the area, could potentially allow the use of these highly reactive compounds. Such a strategy requires that little or none of the material reach systemic circulation to cause off-target toxicities. If this approach were applied to cancer, multiple mechanisms could be activated to disrupt cellular metabolism. We report our experience in a swine model using a strong electrophile, dichloroacetyl chloride, dissolved in a hydrophobic vehicle and delivered to the liver with high spatial selectivity using a microcatheter. Compared with positive controls, very little of the reaction product, dichloroacetate, a known inhibitor of pyruvate dehydrogenase kinase, was detected in plasma over 4 h. We further demonstrated persistence of the material for 24 h with highly localized and well-defined coagulative necrosis in the target vascular bed, without evidence of dose-limiting toxicity over the duration of the experiment.

Identifiers

PMID40242576
PMCPMC11997884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.